AI Trends

Isomorphic Labs Secures Largest Single-Round Financing in AI Pharma, Total Funding Reaches $7.7 Billion

cnBetaUpdated Nov 18 14:09

AI summary

Google-affiliated AI pharma company Isomorphic Labs has completed a new funding round, setting a new global record for the largest single-round financing in the AI pharma sector, with total publicly disclosed funding reaching $7.7 billion. Founded by Demis Hassabis, the company's core technologies are the drug design engine IsoDDE and a proprietary Agent for exploring complex biological systems, and it has established R&D collaborations with pharmaceutical companies including Novartis, Eli Lilly, and Johnson & Johnson. In January this year, Hassabis said he expected to launch the first clinical trials before the end of 2026, a delay from the previous target of the end of 2025.

Why read this

AI score 65

Isomorphic Labs has raised another massive round within six months, but the timeline for its first clinical trials has been delayed, giving readers a clear view of the gap between capital enthusiasm and the validation cycle in AI pharma.

Topics

Tags

Body · AI translation

This round of financing set a new record for the largest single round of financing in the global AI pharmaceutical field, and it comes only half a year after Isomorphic Labs' previous round. In May of this year, the company had just secured $2.1 billion in Series B financing, which also set a record for a single financing in the global AI pharmaceutical industry at the time. Together with the $600 million in first external financing completed in March 2025, this company, founded only five years ago, has disclosed a cumulative total of $7.7 billion in financing.

Isomorphic Labs was founded in the United Kingdom by Demis Hassabis, a Nobel laureate in chemistry and former co-founder of Google DeepMind. The company was spun out of Google DeepMind in 2021, with Hassabis serving as CEO. In August of this year, after Hassabis stepped down as CEO of Google DeepMind, he focused his attention on the long-term AGI strategy, the social impact of AI, and this AI pharmaceutical company, Isomorphic Labs.

Why are investors willing to pour huge sums into an AI company that does not yet have a drug on the market? For Hassabis, this is the next major scientific breakthrough he is trying to achieve with AI, following AlphaFold's success in predicting protein structures.

Traditional new drug development is a long and expensive process. Researchers need to search through massive numbers of compounds for potentially effective candidate molecules, then repeatedly optimize their efficacy, safety, and other characteristics through experiments. Even after entering clinical trials, the risk of eventual failure remains high.

Isomorphic Labs hopes to greatly improve the efficiency of this process through AI. Its core technology is a proprietary drug design engine, IsoDDE, which integrates a series of foundational simulation AI models covering multiple therapeutic areas and different drug types, and can explore chemical space to help R&D teams design, screen, and optimize molecules with desirable drug-like properties.

In addition to simulation models, the company has also developed proprietary Agents for exploring complex biological systems and performing reasoning. Isomorphic Labs says that combining models with Agents has advanced pipelines of multiple types of drug candidates. At present, the company's internal oncology and immunology projects as well as collaborative projects have achieved preclinical results.

Isomorphic Labs says it has established R&D partnerships with large pharmaceutical companies such as Novartis, Eli Lilly, and Johnson & Johnson to explore the application of AI in different drug development projects.

In a blog post, Hassabis mentioned that when Isomorphic Labs was founded, the team believed that biology could be understood and modeled at the most fundamental molecular level, and that AI could significantly accelerate this process. According to him, this round of financing will help the company further develop foundational biology models, increase understanding of disease mechanisms, and advance the first batch of therapeutic programs into clinical trials to provide patients with a new generation of medicines.

However, in contrast to the huge financing, Isomorphic Labs still has a long way to go before it can launch a drug that can be sold on the market.

In January of this year, Hassabis said at the World Economic Forum in Davos that the company expected to initiate its first clinical trials by the end of 2026. This timetable has already been delayed compared with the previously stated target of the end of 2025.

This is also the core problem that the AI pharmaceutical industry has not yet solved: although AI can accelerate the discovery of drug molecules, whether these molecules can become safe and effective drugs still requires lengthy validation. Drug development must not only prove that it can treat human diseases, but also ensure that it does not produce major side effects.

Some industry practitioners believe that although huge amounts of capital are betting on the AI drug R&D field, the risk of clinical trial failure remains high, "because huge sums of money cannot guarantee a market-ready drug." Improved model predictive capability does not mean that the entire clinical development cycle can be shortened proportionally.

Isomorphic Labs is undergoing another form of commercialization test in the AI industry. Over the past few years, the market has been accustomed to evaluating the value of AI companies through model rankings, generation speed, and user scale. But in the pharmaceutical field, model performance is only the starting point; ultimately, clinical trial results are needed to prove the actual value of the technology.

Compared with "half of the timeline being spent on spending billions of dollars to make chatbots more interesting," some netizens believe that spending $5 billion to tackle diseases seems more worthy of attention. If AI's first truly killer application is not an app but a drug, that is the plot twist he is looking forward to.

Source

cnBeta